1.83

2.23% 0.04

After Hours: 1.80 -0.03 -1.64%

Prokidney Corp (PROK)

Overview News Price History Option Chain Financials Discussions Forecast

Prokidney Corp stock is traded at $1.83, with a volume of 810.61K. It is up +2.23% in the last 24 hours and down -19.03% over the past month. ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.

Previous Close:

$1.79

Open:

$1.85

24h Volume:

810.61K

Relative Volume:

0.91

Market Cap:

$259.76M

Revenue:

$893.00K

Net Income/Loss:

$-151.61M

P/E Ratio:

-3.552

EPS:

-0.5152

Net Cash Flow:

$-135.31M

1W Performance:

-12.02%

1M Performance:

-19.03%

6M Performance:

-30.15%

1Y Performance:

+81.19%

1-Day Range:

$1.80

$1.90

1-Week Range:

$1.78

$2.10

52-Week Range:

$0.4603

$7.13

Prokidney Corp Stock (PROK) Company Profile

Name

Prokidney Corp

Sector

Healthcare (1114)

Industry

Biotechnology (623)

Phone

336-999-7028

Address

2000 FRONTIS PLAZA BLVD., WINSTON-SALEM

Employee

231

Twitter

Next Earnings Date

2026-03-16

Latest SEC Filings

PROK's Discussions on Twitter

Compare PROK vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PROK Prokidney Corp	1.83	254.08M	893.00K	-151.61M	-135.31M	-0.5152
VRTX Vertex Pharmaceuticals Inc	454.97	113.96B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	749.47	78.41B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.70	40.85B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	697.05	42.05B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	148.31	29.99B	606.42M	-1.28B	-997.58M	-6.403

Prokidney Corp Stock (PROK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-16-25	Initiated	H.C. Wainwright	Buy
Jun-30-25	Downgrade	BofA Securities	Neutral → Underperform
Sep-30-24	Initiated	JP Morgan	Neutral
Sep-10-24	Initiated	Guggenheim	Buy
Mar-07-24	Resumed	Morgan Stanley	Equal-Weight
Jan-02-24	Downgrade	BofA Securities	Buy → Neutral
Jul-25-23	Initiated	BTIG Research	Buy
Dec-21-22	Initiated	Jefferies	Buy
Nov-10-22	Initiated	Morgan Stanley	Equal-Weight
Oct-18-22	Initiated	UBS	Buy
Oct-14-22	Initiated	Citigroup	Buy
Sep-23-22	Initiated	BofA Securities	Buy
Sep-02-22	Initiated	Evercore ISI	Outperform

View All

Prokidney Corp Stock (PROK) Latest News

Mar 25, 2026

ProKidney appoints Greg Madison as chief commercial officer - TipRanks

Mar 25, 2026

ProKidney names Greg Madison as chief commercial officer - Investing.com

Mar 25, 2026

ProKidney names Greg Madison as chief commercial officer By Investing.com - Investing.com UK

Mar 25, 2026

Prokidney Corp. Appoints Greg Madison as Chief Commercial Officer - marketscreener.com

Mar 25, 2026

Mar 24, 2026

ProKidney (NASDAQ:PROK) Trading Down 7.6%Here's What Happened - MarketBeat

Mar 24, 2026

Mar 23, 2026

Q2 Earnings Forecast for ProKidney Issued By HC Wainwright - MarketBeat

Mar 23, 2026

Mar 22, 2026

ProKidney Corp. (NASDAQ:PROK) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Mar 22, 2026

Mar 21, 2026

Insider Sell: Does ProKidney Corp offer margin of safety2026 Outlook & Capital Efficiency Focused Ideas - baoquankhu1.vn

Mar 21, 2026

ProKidney (NASDAQ:PROK) Cut to Sell at Wall Street Zen - MarketBeat

Mar 21, 2026

Mar 20, 2026

ProKidney narrows loss to $150M as it eyes crucial kidney treatment trial results - The Business Journals

Mar 20, 2026

Analysts Offer Insights on Healthcare Companies: ProKidney (PROK), Molecular Partners (MOLN) and Bristol-Myers Squibb (BMY) - The Globe and Mail

Mar 20, 2026

Equities Analysts Set Expectations for ProKidney Q1 Earnings - MarketBeat

Mar 20, 2026

Guggenheim Sticks to Its Buy Rating for ProKidney (PROK) - The Globe and Mail

Mar 20, 2026

ProKidney’s Greensboro Facility Could Shield It From Looming Tariff Risks—But Time Is Short - Bitget

Mar 20, 2026

Trade Policy Risks: How Evolving U.S. Tariffs and Export Rules Threaten ProKidney Corp.’s Supply Chain and Financial Stability - TipRanks

Mar 20, 2026

Mar 19, 2026

ProKidney Makes Major Wager on U.S. Tariff Relief—Does Consistent Policy Support a $485M Risk? - Bitget

Mar 19, 2026

ProKidney ends fiscal 2025 with bigger loss, larger revenue stream - Winston-Salem Journal

Mar 19, 2026

ProKidney: Extended Development Timeline and Deferred Catalysts Support Balanced Hold Rating - TipRanks

Mar 19, 2026

ProKidney (NASDAQ:PROK) Raised to "Strong-Buy" at Jefferies Financial Group - MarketBeat

Mar 19, 2026

Mar 18, 2026

BofA reiterates ProKidney stock Underperform rating at $1 target By Investing.com - Investing.com South Africa

Mar 18, 2026

ProKidney Corp. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com

Mar 18, 2026

BofA reiterates ProKidney stock Underperform rating at $1 target - Investing.com

Mar 18, 2026

ProKidney (NASDAQ:PROK) Releases Earnings Results - MarketBeat

Mar 18, 2026

ProKidney Reports Full Year 2025 Financial Results and Business Highlights - Bitget

Mar 18, 2026

PROK: FDA alignment, strong clinical progress, and cash runway into 2027 despite ongoing losses - TradingView

Mar 18, 2026

ProKidney (Nasdaq: PROK) details 2025 loss and cash runway into 2027 - Stock Titan

Mar 18, 2026

ProKidney (PROK) advances Phase 3 rilparencel program for diabetic CKD - Stock Titan

Mar 18, 2026

ProKidney’s High Cash Usage Dims Pipeline Hopes—Investors Brace for Funding Shortfall Before 2027 Results - Bitget

Mar 18, 2026

Mar 17, 2026

ETF Watch: How volatile is ProKidney Corp stock2026 PreEarnings & Entry and Exit Point Strategies - baoquankhu1.vn

Mar 17, 2026

Aug Update: Why is ProKidney Corp stock going downRisk Management & AI Powered Market Entry Ideas - baoquankhu1.vn

Mar 17, 2026

Mar 16, 2026

ProKidney (NASDAQ:PROK) Stock Price Down 4.7%Time to Sell? - MarketBeat

Mar 16, 2026

Dividend Watch: Is ProKidney Corp stock undervalued right now2026 Update & Real-Time Price Movement Reports - baoquankhu1.vn

Mar 16, 2026

Mar 13, 2026

ProKidney’s Unclear Messages Leave Traders Puzzled - Bitget

Mar 13, 2026

Mar 12, 2026

Portfolio Shifts: Is ProKidney Corp impacted by rising ratesOptions Play & AI Powered Trade Plan Recommendations - baoquankhu1.vn

Mar 12, 2026

Mar 11, 2026

Meet the Biotech Stock That Rocketed 775% Higher - MSN

Mar 11, 2026

Prokidney Corp expected to post a loss of 12 cents a shareEarnings Preview - TradingView

Mar 11, 2026

Mar 10, 2026

Momentum Shift: Is ProKidney Corp stock undervalued right nowWeekly Trade Recap & Reliable Volume Spike Alerts - baoquankhu1.vn

Mar 10, 2026

Mar 09, 2026

ProKidney (PROK) Projected to Post Earnings on Monday - MarketBeat

Mar 09, 2026

Mar 07, 2026

ProKidney, FDA align on accelerated approval pathway for Rilparencel - MSN

Mar 07, 2026

Can ProKidney Corp. stock hit record highs again2026 Fundamental Recap & Safe Entry Zone Tips - Naître et grandir

Mar 07, 2026

Mar 06, 2026

Why ProKidney Corp. stock could outperform in 2026Rate Cut & AI Enhanced Trading Alerts - Naître et grandir

Mar 06, 2026

Smart Money: Is ProKidney Corp impacted by rising rates2025 AllTime Highs & Breakout Confirmation Trade Signals - baoquankhu1.vn

Mar 06, 2026

Wall Street Recap: Does ProKidney Corp offer margin of safetyQuarterly Portfolio Review & Long-Term Safe Investment Ideas - baoquankhu1.vn

Mar 06, 2026

Mar 04, 2026

ProKidney (NASDAQ:PROK) Stock Price Up 9%Here's Why - MarketBeat

Mar 04, 2026

Mar 03, 2026